PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. completed its de-SPAC transaction through FS Development Corp. II, which traded under the ticker FSII on the Nasdaq. The blank-check company was sponsored by Foresite Capital's FS Development Holdings II, LLC and completed its IPO in 2021, targeting opportunities in the healthcare and biopharmaceutical sector. The S-1/A amendment filed on January 28, 2022 advanced the registration process for Pardes Biosciences, a clinical-stage antiviral drug developer whose lead program focused on COVID-19 oral therapeutics. The filing reflects the combined company's progression through the SEC review cycle ahead of closing the business combination. Visit SpacDesk and sign up for full data, filings history, and deal analytics on this transaction and hundreds more.